J Fluoresc (2010) 20:1275–1285
1285
deviation. The results are abridged in Table 7. Figure 9
illustrates the second derivative synchronous fluorescence
spectroscopy (SDSFS) in real human plasma.
19. Al-Angary AA, Khadr SH, Abd-Elhady SS, Bayomi MA,
Mahrous GM (1992) Anal Lett:1251–1260
20. Hoogewijs G, Massart DL (1986) J Chromatogr Biomed Appl
50:391–398
21. De-Schutter JA, De-Croo F, Van-der-Weken G, Van-den-Bossche
W, De-Moerloose P (1985) Chromatographia 20:185–192
22. Zheng T, Li SF, Xu BZ (1999) Yaowu-Fenxi-Zazhi 19:10–12
23. Buna M, Aaron JJ, Prognon P, Mahuzier G (1996) Analyst
(Cambridge,UK) 121:1551–1556
24. Nie JF, Wu HL, Xia AL, Zhu SH, Bian YC, Li SF, Yu RO (2007)
Anal Sci 23:1377–1382
25. Farghaly OAEM (2000) J Pharm Biomed Anal 23:783–791
26. Zeng YH, Song Q (1997) Fenxi-Huaxue 25:56–58
27. Yamamoto E, Sakaguchi T, Kajima T, Mano N, Asakawa NJ
(2004) Chromatogr B 807:327–334
28. Wang JZ, Xu X, Hu JG, Li J (2004) Fenxi-Ceshi-Xuebao 23:121–122
29. Matthijs N, Perrin C, Maftouh M, Massrat DL, Vander-Heyden Y
(2004) J Chromatogr A 1041:119–133
30. Kagan M, Chlenov M, Kraml CM (2004) J Chromatogr A
1033:321–331
31. Liu SL, Liu CH, Qin YJ, Zhao QQ, Liu XX, Li FL (2002) Yaowu-
Fenxi-Zazhi 22:365–368
32. Chiba R, Ogasawara A, Kubo T, Yamazaki Y, Umino M, Ishizuka
Y (2003) Anal Sci 19:785–790
Conclusion
A new simple and sensitive method was explored for the
simultaneous determination of MEB and SUL in their
combined tablets. The first derivative synchronous spectro-
fluorimetric method, by virtue of its high sensitivity, could be
applied to the analysis of both drugs in their co-formulated
dosage forms and biological fluids. It was possible to measure
concentrations as low as 0.01 and 0.006 µg/mL for MEB and
SUL respectively with good accuracy Moreover, first deriv-
ative spectrofluorimetric technique enables the determination
of MEB in the presence of SUL by applying the zero-crossing
technique in the spectra without prior separation steps in their
pure form. Also, the proposed method allowed therapeutic
monitoring of MEB metabolite (veratic acid) in real human
plasma without interference with SUL. Moreover, the
proposed method is simple, time saving and other advantage
of the method is the use of low cost reagent.
33. Huang MC, Ho HO, Yeh GC, Ke WT, Lin LC, Hsu TMB, Sheu
MT (2002) Yaowu-Shipin-Fenxi 10:1–6
34. Huang MC, Ho HO, Yeh GC, Ke WT, Lin LC, Hsu TMB, Kao
CC, Sheu MT (2001) J Chromatogr B 763:157–163
35. Zhang ZL, Zhou JL (2007) J Chromatogr A 1154:205–213
36. Hassib ST, Moussa BA, Hashim HA, El-Zaher AA (2002)
Spectrosc Lett 35:43–61
37. El-Walily AFM, El-Gingy A, Bedair MF (1999) J Pharm Biomed
Anal 21:535–548
38. Zayed SIM (2005) Anal Sci 21:985–998
References
39. Chen GZ, Huang XZ, Xu JG, Zheng ZZ, Wang ZB (1990) The
methods of fluorescence analysis, 2nd edn. Science, Beijing, 112
40. Patra D, Mishra AK (2002) Anal Chem 21:787
42. Murillo Pulgarin JA, Alanon Molina A, Fernandez Lopez P
(1998) Anal Chim Acta 370:9–18
1. Sweetman SC (2007) Martindale: the complete drug reference,
35th edn. The Pharmaceutical Press, London, pp 119–692
2. The British Pharmacopoeia, The Stationary Office, London, 2007
(electronic version)
3. El-Didamony AM (2008) Spectrochim Acta 69:770–775
4. Shama SA, Amin AS (2004) Spectrochim Acta 60:1769–1774
5. Sreedhar K, Sastry CSP, Reddy MN, Sankar DG (1997)
Mikrochim Acta 131–135
43. Walash MI, Belal F, El-Enany N, Abdelal AA (2008) J Fluoresc
18:61–74
6. Reddy MN, Rao KVS, Sankar DG, Sridhar K (1996) Indian
Drugs 33:604–606
7. Hassan EM, Gazy AA, Bedair MM (1995) Drug Dev Ind Pharm
21:633–638
8. Abdel-Gawad FM (1994) Egypt J Anal Chem 3:129–134
9. Bedair MM, Korany MA, Ebdel-Hay MA, Gazy AA (1990)
Analyst (London) 115:449–453
44. El-Enany N (2008) J AOAC INT 91:542–550
45. Wei YF, Li XH, Ma DM (2005) Guang Pu Xue Yu Guang Pu Fen
Xi 25:588–590
46. Murillo Pulgarín JA, Alañón Molina A, Fernández López P,
Sánchez-Ferrer Robles I (2007) Anal Chim Acta 583:55–62
47. Xiao Y, Wang HY, Han J (2005) Acta A Mol Biomol Spectrosc
61:567–573
10. Ibrahim H, Issa YM, Abu-Shawish HM (2007) J Pharm Biomed Anal
44:8–15
11. Ibrahim H, Issa YM, Abu-Shawish HM (2005) J Pharm Biomed
Anal 36:1053–1061
12. Perrin C, Vander-Heyden Y, Maftouh M, Massart DL (2001)
Electrophoresis 22:3203–3215
13. De-Schutter JA, Van-Der-Weken G, Van-den-Bossche W, De-
Moerloose P (1985) J Chromatogr 20:739–742
14. De-Schutter JA, Van-Der-Weken G, Van-den-Bossche W, De-
Moerloose P (1985) J Chromatogr 350:135–144
15. Radwan MA, Abdine HH, Aboul-Enein HY (2006) Biomed
Chromatogr 20:211–216
16. Elliott S, Burgess V (2006) J Anal Toxicol 30:91–97
17. Arayne MS, Sultana N, Siddiqui FA (2005) J Pharm Sci 18:11–14
18. Al-Deep O, Al-Hadiya BM, Foda NH (1997) Chromatographia
44:427–430
48. Abdelal A, El-Enany N, Belal F (2009) Talanta 80:880–888
49. De-Schutter J, De-Croo F, Van-der-weken G, Van-den-Bossche W,
De-Moerloose P (1985) Chromatographia 20:185–192
50. The United States Pharmacopoeia USP30 (2007) (electronic
version)
51. ICH Harmonized Tripartite Guideline, Validation of analytical
procedures: Text and methodology, Q2(R1), Current Step 4
Version, Parent Guid lines ON Methodology Dated November 6,
52. Miller JC, Miller JN (2005) Statistics and chemometrics for
analytical chemistry, 5th edn. Printce Hall, England, 256
53. Ronald G, Peter V, Mechael E, Wayne D (1991) J Pharm Sci
80:952–957
54. Stockis A, Guelen PJM, de Vos D (2001) J Pharm Biomed Anal
29:335–340